Bayer AG’s failure to identify weaknesses in Merck & Co.’s over the counter drug business before it bought it in 2014 sets a problematic precedent for its latest acquisition, an M&A expert told me today. Why? Read my piece for the Wall Street Journal’s CFO Journal.